WY-14643 (Pirinixic Acid)

Catalog No.S8029 Batch:S802905

Print

Technical Data

Formula

C14H14ClN3O2S

Molecular Weight 323.8 CAS No. 50892-23-4
Solubility (25°C)* In vitro DMSO 65 mg/mL (200.74 mM)
Ethanol 16 mg/mL (49.41 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
3.25mg/ml Taking the 1 mL working solution as an example, add 50 μL 65 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description WY-14643 (Pirinixic Acid, NSC 310038) is a potent and selective PPARα activator with an EC50 of 1.5 μM.
Targets
PPARα [1]
1.5 μM(EC50)
In vitro

WY 14643 (10 μM) almost completely inhibits interleukin-1-induced production of interleukin-6 and prostaglandin and expression of cyclooxygenase-2 in aortic smooth-muscle cells, through repression of NF-κB signaling. [2] WY14643 (250 μM) reduces VCAM-1 expression levels significantly, to 52 % of TNF-α-stimulated human endothelial cells. Pretreatment of endothelial cells with WY 14643 (10 μM) before TNF-α stimulation reduces U937 cell adhesion by 50%. [3]

In vivo

WY 14643 (1 mg/kg i.v. bolus) administration at 30 min before left anterior descending occlusion, causes significant reduction in infarct size of ∼44% in rats subjected to regional myocardial ischemia (25 min) and reperfusion (2 h). [4] WY 14643 (3 mg/kg) lowers basal plasma levels of glucose, triglycerides (-16% vs. untreated), and leptin (-52%), and also muscle triglyceride (-34%) and total long-chain acyl-CoAs (LCACoAs) (-41%) in high fat-fed rats. WY14643 substantially reduces visceral fat weight and total liver triglyceride content without increasing body weight gain. WY14643 enhances whole body insulin sensitivity (clamp glucose infusion rate increases 35% and glucose disposals 22%, vs. untreated). WY 14643 enhances insulin-mediated muscle glucose metabolic index (Rg') in red (47%) and white (63%) muscles as well as in white adipose tissue (90%), and reduces muscle triglyceride and LCACoA accumulation. [5]

Protocol (from reference)

Customer Product Validation

Data from [Data independently produced by , , Diabetes, 2017, 66(8):2112-2123]

Selleck's WY-14643 (Pirinixic Acid) has been cited by 18 publications

Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity [ Front Pharmacol, 2024, 15:1366479] PubMed: 38595921
Inhibition of ACOX1 enhances the therapeutic efficacy of obeticholic acid in treating non-alcoholic fatty liver disease and mitigates its lipotoxicity [ Front Pharmacol, 2024, 15:1366479] PubMed: 38595921
mTORC2 Facilitates Liver Regeneration Through Sphingolipid-Induced PPAR-α-Fatty Acid Oxidation [ Cell Mol Gastroenterol Hepatol, 2022, 14(6):1311-1331] PubMed: 35931382
Oroxylin A ameliorates AKI-to-CKD transition through maintaining PPARα-BNIP3 signaling-mediated mitochondrial homeostasis [ Front Pharmacol, 2022, 13:935937] PubMed: 36081929
Overexpression CPT1A reduces lipid accumulation via PPARα/CD36 axis to suppress the cell proliferation in ccRCC [ Acta Biochim Biophys Sin (Shanghai), 2022, 54(2):220-231] PubMed: 35130611
Critical role of peroxisome proliferator-activated receptor α in promoting platelet hyperreactivity and thrombosis under hyperlipidemia [ Haematologica, 2021, 10.3324/haematol.2021.279770] PubMed: 34615341
PPARα agonist WY-14,643 enhances ethanol metabolism in mice: Role of catalase [ Free Radic Biol Med, 2021, 169:283-293] PubMed: 33892114
CircRNA hsa_circ_0110102 inhibited macrophage activation and hepatocellular carcinoma progression via miR-580-5p/PPARα/CCL2 pathway [ Aging (Albany NY), 2021, 13(8):11969-11987] PubMed: 33891564
Fatter or stronger: Resource allocation strategy and the underlying metabolic mechanisms in amphibian tadpoles [ Comp Biochem Physiol Part D Genomics Proteomics, 2021, 38:100825] PubMed: 33770735
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling. [ Genes Dev, 2020, 34(7-8):526-543] PubMed: 32079652

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.